Menin-MLL inhibitor 20 is primarily used in research and therapeutic applications targeting cancers associated with MLL (Mixed-Lineage Leukemia) gene rearrangements. It works by disrupting the interaction between menin and MLL fusion proteins, which are critical for the development and progression of certain leukemias. This inhibitor is particularly valuable in preclinical studies for understanding the molecular mechanisms of MLL-rearranged leukemias and for developing targeted therapies. Its potential as a therapeutic agent is being explored in the treatment of acute leukemias, where it shows promise in inhibiting cancer cell growth and survival. Additionally, it serves as a tool for studying epigenetic regulation and gene expression in cancer biology.